EVOLUS, INC. Deferred Foreign Income Tax Expense (Benefit)
EVOLUS, INC. (EOLS) reported Deferred Foreign Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-03-03
- EVOLUS, INC. deferred foreign income tax expense (benefit) for fiscal 2025 was $0.00.
- EVOLUS, INC. deferred foreign income tax expense (benefit) for fiscal 2024 was $0.00.
- EVOLUS, INC. deferred foreign income tax expense (benefit) for fiscal 2023 was $0.00.
- EVOLUS, INC. deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-04 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |